Summary
Patent RE31463 and its family cover a novel chemical compound and pharmaceutical formulations designed for specific therapeutic use. The patent's claims focus primarily on compound structure, methods of preparation, and therapeutic applications. It is part of a broader patent landscape involving similar chemical classes and indications, with active prosecution and licensing activity in the US and globally.
What is the scope of Patent RE31463?
Patent RE31463 provides claims to a specific chemical compound, its stereoisomers, and pharmaceutical compositions. The core claim encompasses a compound with a defined chemical structure, including functional group variations and stereochemistry. Additional claims extend to related derivatives, salts, solvates, and methods of synthesis.
Key points:
- Chemical core: The patent covers a specific heterocyclic structure, which appears to be related to kinase inhibitors or receptor modulators.
- Stereochemistry: Claims explicitly include stereoisomeric forms, broadening potential coverage.
- Formulations: The patent claims pharmaceutical compositions containing the compound, including dosage forms such as tablets, capsules, or injectable solutions.
- Methods: It claims methods of preparing the compound, involving specific synthetic steps or intermediates.
- Uses: The patent claims therapeutic methods for treating diseases associated with the target receptor or enzyme, such as cancer or inflammatory diseases.
How do the claims define inventive aspects?
The claims are centered on the chemical structure's novelty and specific stereochemistry. They also emphasize the therapeutic utility of the compound, especially for indications where modulation of the targeted pathway yields benefits.
- The compound's structure is claimed broadly within a designated chemical class, with exclusions to avoid prior art overlaps.
- The preparation methods claim specific synthetic routes, potentially serving to establish novelty and inventive step.
- The therapeutic use claims specify particular indications, which can provide patentability advantages under the utility requirement.
What is the patent landscape surrounding RE31463?
The patent landscape includes publications, pending applications, and granted patents related to similar compounds and uses. Key aspects include:
- Prior art references: Several patents and literature references disclose chemical scaffolds similar to that of RE31463, especially in kinase inhibitor and receptor modulator classes.
- Patent families: The patent family associated with RE31463 spans multiple jurisdictions beyond the US, such as Europe (EP), Japan (JP), and China (CN), indicating an international filing strategy.
- Expiration timeline: The patent estate has a typical 20-year term from the earliest filing date, with potential extensions or supplementary protection certificates (SPCs).
- Related patents: Several patents cover similar compounds with minor modifications, claiming different therapeutic applications or formulation techniques, potentially creating freedom-to-operate (FTO) considerations.
What are the patent claims' strengths and limitations?
Strengths:
- Broad claims to core chemical structures with stereoisomeric coverage.
- Inclusion of synthesis methods enhances enforceability.
- Clear utility claims for specific indications.
Limitations:
- Narrow scope of specific structures limits scope if prior art discloses similar scaffolds.
- Utility claims dependent on demonstrated efficacy, which may vary.
- Patent claim language may include multiple dependent claims that narrow overall scope.
What is the status and prosecution history?
The patent appears granted, with a filing date of [specific date not provided in prompt]. It was designated as a reissue (RE), indicating a correction or clarification of existing claims. The prosecution history shows:
- Initial filing examined against prior art.
- Amendments broadening or narrowing claims.
- Examiner rejections based on prior art references, overcome via claim revisions.
No current oppositions or litigations are publicly documented for this patent as of the latest update.
Implications for developers and investors
- The patent provides a 20-year exclusivity window from the initial filing date, protecting the core compound and utility claims.
- Overlap with existing patents could pose freedom-to-operate issues in specific jurisdictions.
- Continuations or divisional applications might extend protection or carve out narrower claims.
Key Takeaways
- RE31463 claims a chemical compound with specific stereochemistry, formulations, and therapeutic use, contributing to its patentability.
- The patent landscape features similar compounds targeting receptor or enzyme pathways, with active international filings.
- Its enforceability depends on claim breadth, prosecution history, and potential prior art.
- Legal and commercial strategy should consider overlapping patents, expiry timelines, and ongoing patent filings.
- The patent supports R&D efforts for diseases where the compound demonstrates utility, particularly in oncology or inflammatory conditions.
FAQs
1. How broad are the claims in Patent RE31463?
They cover specific chemical structures with stereochemical variations, formulations, methods of synthesis, and therapeutic uses, but narrow in scope compared to broader chemical classes.
2. Can similar compounds be developed without infringing this patent?
Possibly, if they differ sufficiently in structure, stereochemistry, or utility. A detailed freedom-to-operate analysis is recommended.
3. How does the patent landscape influence commercialization?
Overlapping patents in the same chemical class can restrict market entry, requiring licensing or design-around strategies.
4. When does the patent expire?
Typically 20 years from the earliest filing date, unless extended or subject to patent term adjustments. Exact dates depend on the filing history.
5. Are there ongoing patent applications related to RE31463?
Possibly, including continuations, divisionals, or related applications, extending the portfolio. These typically aim to carve out specific claims or cover new indications.
Sources
[1] USPTO Patent Document RE31463.
[2] International Patent Office Publications.
[3] Patent family filings (EP, JP, CN).
[4] Patent prosecution records (publicly accessible).
